Market Turbulence Hits A2B, Alumina, Healius, and Nuix Stocks

The S&P/ASX 200 Index is experiencing a subdued end to the week, down 0.15% at 7,495.6 points in afternoon trade. However, several ASX-listed stocks are facing more significant declines. Here's a breakdown of why A2B Australia Ltd (ASX: A2B), Alumina Limited (ASX: AWC), Healius Ltd (ASX: HLS), and Nuix Ltd (ASX: NXL) are witnessing drops:

A2B Australia Ltd (ASX: A2B):

The A2B share price plummeted by 33% to AU$1.41, as the taxi payments company went ex-dividend for a special dividend of 60 cents per share, payable on January 30. The dividend proceeds were generated from the $78 million sale of 9-13 O'Riordan Street, Alexandria.

Alumina Limited (ASX: AWC):

Alumina shares dipped 2.5% to AU$1.10, likely due to profit-taking after a recent surge. The heightened demand for shares followed partner Alcoa's decision to curtail production at the loss-making Kwinana operation.

Healius Ltd (ASX: HLS):

Healius share price saw a 5% drop to AU$1.50, following a downgrade by Morgan Stanley. The healthcare company's shares were downgraded to an underweight rating, with a AU$1.30 price target. Concerns over significant earnings uncertainty and doubts about its earnings guidance prompted the downgrade.

Nuix Ltd (ASX: NXL):

Nuix shares tumbled 13% to AU$1.82 after the release of a half-year update. Although Nuix expects an annualised contract value (ACV) of AU$196 million to AU$199 million, reflecting a 15% to 17% increase over the prior corresponding period, the market's high expectations were not fully met. Despite being on track to achieve its FY 2024 target, the shares fell as investors hit the sell button, given the company's remarkable 150% surge in the last 12 months.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com